SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 3/4/2015 6:44:41 PM - Followers: 35 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for GALT
GALT News: Galectin Therapeutics to Present at the 27th Annual ROTH Conference 03/02/2015 10:57:38 AM
GALT News: Current Report Filing (8-k) 02/24/2015 08:02:31 AM
GALT News: Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 02/24/2015 08:00:00 AM
GALT News: Current Report Filing (8-k) 02/24/2015 07:54:34 AM
GALT News: Statement of Changes in Beneficial Ownership (4) 02/03/2015 05:03:25 PM
PostSubject
#1840   Dr David Shapiro (CMO) from Intercept is the Tesla1 03/04/15 06:44:41 PM
#1839   Saturday, March 21 Tesla1 03/04/15 06:23:59 PM
#1837   Wow. Based on what you believe, he certainly thefamilyman 02/26/15 01:59:27 PM
#1836   sticking to objective data is a good idea oldsport 02/26/15 01:30:46 PM
#1835   Knowing Traber, there will not be any compassionate IRAHopeful 02/26/15 01:25:08 PM
#1834   back in today... oldsport 02/26/15 01:21:59 PM
#1830   They're talking about a different stock jmh0602 02/26/15 10:13:39 AM
#1828   It is already on NASADAQ (since the reverse biotech2010 02/26/15 08:14:25 AM
#1827   once it makes nsdq i will buy, plenty oldsport 02/25/15 07:04:46 PM
#1826   Less risk there than there is here from Darwinian 02/25/15 05:57:08 PM
#1825   I want to change my statement (in bold) thefamilyman 02/25/15 05:10:57 PM
#1823   OK, that helps. Maybe it's a worst case Darwinian 02/25/15 11:57:05 AM
#1822   from 8k it was understood study was flexible oldsport 02/25/15 10:49:51 AM
#1821   From the presentation they are expecting enrolment to DirectionalDriller 02/25/15 10:46:41 AM
#1820   So much for having the FDA's "Fast Track" designation... thefamilyman 02/25/15 10:42:27 AM
#1819   Under the original protocol, longs had reason to thefamilyman 02/25/15 10:37:38 AM
#1818   I had the same question but found the jmh0602 02/25/15 10:31:45 AM
#1817   had same question myself, but look at cohort, oldsport 02/25/15 09:27:56 AM
#1816   Does anyone have any thoughts about what seem Darwinian 02/25/15 09:10:50 AM
#1815   ok bright eye... gotcha oldsport 02/25/15 09:08:54 AM
#1813   You really took my comment out of context-I biotech2010 02/25/15 08:31:31 AM
#1812   i wonder if anyone has personal past history oldsport 02/24/15 08:54:20 PM
#1811   This was a great PR and yet our thefamilyman 02/24/15 06:27:26 PM
#1810   Thanks biotech. Your input is very welcome. Adi2 02/24/15 12:49:22 PM
#1809   fx is done 2016, cx is due by 2018 oldsport 02/24/15 12:41:37 PM
#1808   So the NASH-CX trials last a year and jmh0602 02/24/15 12:36:47 PM
#1807   looks like 8k is pretty good... pps still oldsport 02/24/15 09:47:35 AM
#1806   Thanks Biotech2010, Darwinian 02/24/15 08:54:38 AM
#1805   With today's Phase 2 announcement it seems like biotech2010 02/24/15 08:40:17 AM
#1804   looks like i can get back in on oldsport 02/23/15 12:48:14 PM
#1803   been sellin today to recupe losses, hope i oldsport 02/17/15 08:08:35 PM
#1802   The cynic in me says it's probably a thefamilyman 02/13/15 10:44:52 AM
#1801   who the hell is tryin to buy $130k oldsport 02/13/15 10:14:21 AM
#1800   Yeah. I hope that the design of P2 Darwinian 02/04/15 08:55:31 AM
#1799   It's probably contractual. But I will admit that thefamilyman 02/04/15 08:50:02 AM
#1798   Lot of activity by management in the last Darwinian 02/04/15 08:19:39 AM
#1797   The options are worth 259k x3.45=$893550 in cash DirectionalDriller 02/03/15 11:25:11 AM
#1796   $10-17 in ten years oldsport 02/03/15 11:15:13 AM
#1795   so basically these shares are worth $10 in oldsport 02/03/15 10:55:27 AM
#1794   These are options with a strike price of DirectionalDriller 02/03/15 09:32:53 AM
#1793   Can't say I understand exactly what the numbers Darwinian 02/02/15 09:35:38 PM
#1792   can anyone confirm the 450k buy ? oldsport 02/02/15 06:09:58 PM
#1791   anyone read the new form4 yet ? oldsport 02/02/15 06:05:55 PM
#1790   dont quit ur day job bettin on galt... oldsport 02/02/15 05:52:57 PM
#1789   That 450,000 shares in ONE TRADE is the thefamilyman 02/02/15 05:45:10 PM
#1788   That's a pretty big trade... Darwinian 02/02/15 05:19:14 PM
#1787   Anyone have opinions on the 450K T trade shaner 02/02/15 05:06:47 PM
#1786   I thought the presentation was pretty good. thefamilyman 02/02/15 03:53:27 PM
#1785   My understanding is that GALT is supplying the Darwinian 02/02/15 08:22:19 AM
#1784   funding... nash is promising... keytruda i good bc collaborator oldsport 02/02/15 01:47:18 AM
PostSubject